Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer

Ann Oncol. 2000 Feb;11(2):227-8. doi: 10.1023/a:1008349209956.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects
  • Carcinoma, Non-Small-Cell Lung / diagnosis
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Depsipeptides
  • Dose-Response Relationship, Drug
  • Female
  • Follow-Up Studies
  • Humans
  • Infusions, Intravenous
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / mortality
  • Male
  • Middle Aged
  • Oligopeptides / administration & dosage*
  • Oligopeptides / adverse effects
  • Severity of Illness Index
  • Survival Rate
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Depsipeptides
  • Oligopeptides
  • dolastatin 10